Survival after neoadjuvant versus adjuvant chemotherapy in operable hormone receptor-positive HER2-negative breast cancer
Neoadjuvant chemotherapy (NACT) can facilitate tumor downstaging in operable hormone receptor-positive/ human epidermal growth factor receptor 2 (HER2)-negative breast cancer, whereas comparisons of long-term outcome with adjuvant chemotherapy (ACT) inform treatment selection. We compared NACT and ACT in a multicenter retrospective cohort of 2,355 women treated at five Chinese centers between 2013 and 2019. Inverse probability of treatment weighting was used to improve the balance of measured baseline characteristics. After weighting, NACT was associated with shorter disease-free survival (hazard ratio [HR] 1.73, 95% confidence interval [CI] 1.26–2.37, p = 0.001) and overall survival (HR 1.85, 95% CI 1.18–2.90, p = 0.007) compared with ACT. Among patients receiving NACT, adverse associations with survival were more pronounced in clinical nonresponders than in responders. These observational findings suggest that post-treatment clinical response may help stratify prognosis after NACT and support the consideration of baseline risk and expected response when selecting the chemotherapy sequence.
Authors
- Xinmiao Yu (ORCID: https://orcid.org/0000-0002-4268-5672)
- Qiao Cheng (ORCID: https://orcid.org/0000-0002-1164-0877)
- Jia Ming (ORCID: https://orcid.org/0000-0001-5256-0307)
- Yirui Wei (ORCID: https://orcid.org/0009-0001-2963-1557)
- Xiaowei Qi (ORCID: https://orcid.org/0000-0001-6650-3629)
- Chaoyang Li
- Yifeng Li (ORCID: https://orcid.org/0009-0001-3340-8104)
- Lu Gan
- Ming Li
- Xueyi Hou
- Jie Chen
- Hongyuan Li
- Mengyuan Wang
Institutions
- Army Medical University (CN)
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- Breast Center (CH)
- Chongqing Three Gorges Central Hospital (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Southwest Hospital (CN)
- First Hospital of China Medical University (CN)
- Chongqing Cancer Hospital (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- iScience
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1016/j.isci.2026.118223
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Chongqing
- West China Hospital, Sichuan University